Prospects for control of emerging infectious diseases with plasmid DNA vaccines

Journal of Immune Based Therapies and Vaccines

Volumn 7, Issue , 2009, Pages 3-

  Moss, Ronald B ^a,b  

^a VICAL INC   (United States)

^b NexBio Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADJUVANT; DNA; DNA VACCINE; GOLD; NEUTRALIZING ANTIBODY; PLASMID DNA; POLOXAMER; POLYGLACTIN; UNCLASSIFIED DRUG; VAXFECTIN; VIRUS PROTEIN; VIRUS VECTOR; WEST NILE VACCINE;

ANIMAL HEALTH; CLINICAL TRIAL; DNA IMMUNIZATION; DNA SEQUENCE; DRUG INDICATION; DRUG SAFETY; HUMAN; IMMUNOSTIMULATION; INFECTION; INFECTION CONTROL; INFLUENZA VIRUS A H1N1; INJECTION; MELANOMA; NONHUMAN; PANDEMIC; REVIEW; SKIN CANCER; VACCINE PRODUCTION;

EID: 71049159517     PISSN: None     EISSN: 14768518     Source Type: Journal    
DOI: 10.1186/1476-8518-7-3     Document Type: Review

References (38)

1. Roush SW, Murphy TV, . Vaccine-Preventable Disease Table Working Group Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007, 298(18):2155-63. 10.1001/jama.298.18.2155, 18000199.
2. Belshe RB. Implications of the Emergence of a Novel H1 Influenza Virus. N Engl J Med 2009, 18;360(25):2667-8.
3. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990, 247(4949 Pt 1):1465-8. 10.1126/science.1690918, 1690918.
4. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, FeIgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259(5102):1745-9. 10.1126/science.8456302, 8456302.
5. Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB. Gene inoculation generates immune responses against humanimmunodeficiency virus type 1. Proc Natl Acad Sci USA 1993, 90(9):4156-60. 10.1073/pnas.90.9.4156, 46465, 8483929.
6. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992, 356(6365):152-4. 10.1038/356152a0, 1545867.
7. Robinson HL, Hunt LA, Webster RG. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 1993, 11(9):957-60. 10.1016/0264-410X(93)90385-B, 8212843.
8. Martin T, Parker SE, Hedstrom R, Le T, Hoffman SL, Norman J, Hobart P, Lew D. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther 1999, 10(5):759-68. 10.1089/10430349950018517, 10210143.
9. Shedlock DJ, Weiner DB. DNA vaccination: antigen presentation and the induction of immunity. J Leukoc BioI 2000, 68(6):793-806.
10. Schalk JA, Mooi FR, Berbers GAM, van Aerts L, Ovelgonne H, Kimman T. Preclinical and Clinical Safety Studies on DNa vaccines. Huamn Vaccines 2006, 2(2):45-53.
11. Glenting J, Wessels S. Ensuring safety of DNA vaccines. Microb Cell Fact 2005, 4:26. 10.1186/1475-2859-4-26, 1215512, 16144545.
12. Liu MA, Wahren B, Karlsson Hedestam GB. DNA vaccines: recent developments and future possibilities. Hum Gene Ther 2006, 17(11):1051-61. 10.1089/hum.2006.17.1051, 17032152.
13. Lu S. Human versus HIV: round 2 defeat in AIDS vaccine development. Expert RevVaccines 2008, (2):151-3.
14. Schoenly KA, Weiner DB. Human immunodeficiency virus type 1 vaccine development:recent advances in the cytotoxic T-Iymphocyte platform "spotty business". J Virol 2008, 82(7):3166-80. Epub 2007 Nov 7, 10.1128/JVI.01634-07, 2268479, 17989174.
15. Kutzler M, Weiner D. DNA vaccines: ready for prime time?. Nature Reviews Genetics 2008, 9:776-788. 10.1038/nrg2432, 18781156.
16. Wang R, Doolan D, Le TP, Hedstrom RC, Coonaan KM, Charpenvit Y, Jones TR, Hobart P, Margalith M, Ng J, Weiss W, Sedegah M, Taisne CD, Norman JA, Hoffman. Induction of antigen -specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282:476-480. 10.1126/science.282.5388.476, 9774275.
17. Martin JE, Pierson TC, Hubka S, Rucker S, Gordon 11, Enama ME, Andrews CA, Xu Q, Davis BS, Nason M, Fay M, Koup RA, Roederer M, Bailer RT, Gomez PL, Mascola JR, Chang GJ, Nabel GJ, Graham BS. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007, 196(12):1732-40. 10.1086/523650, 2714735, 18190252.
18. Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M, Bailer RT, Gomez PL, Nason M, Mascola JR, Nabel GJ, Graham BS. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 2008, 26(50):6338-6343. Epub 2008 Sep 26, 10.1016/j.vaccine.2008.09.026, 18824060.
19. Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S, Culp J, Burkholder JK, Swain WF, Dixon RM, Widera G, Vessey R, King A, Ogg G, Gallimore A, Haynes JR, HeydenburgFuller D. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000, 19(7-8):764-78. 10.1016/S0264-410X(00)00302-9, 11115698.
20. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccines for influenza is immunogenic in humans. Vaccine 2006, 24(21):4475-81. 10.1016/j.vaccine.2005.08.012, 16150518.
21. Tavel JA, Martin JE, Kelly GG, Enama ME, Shen JM, Gomez PL, Andrews CA, Koup RA, Bailer RT, Stein JA, Roederer M, Nabel GJ, Graham BS, . the Vaccine Research Center 001 Study Team Safety and Immunogenicity of a Gag-Pol Candidate HIV-1 DNA Vaccine Administered by a Needle-Free Device in HIV-1-Seronegative Subjects. J Acquir Immune Defic Syndr 2007, 44(5):601-605. 10.1097/QAI.0b013e3180417cb6, 2365751, 17325604.
22. Martin JE, Sullivan NJ, Enama ME, Gordon 11, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, Andrews CA, Moodie Z, Gu L, Stein JA, Nabel GJ, Graham BS. A DNA vaccine for Ebolavirus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006, 11:1267-77. Epub 2006 Sep 20.
23. Otten G, Schaefer M, Doe B, Liu H, Srivastava I, zur Megede J, O'Hagan D, Donnelly J, Widera G, Rabussay D, Lewis MG, Barnett S, Ulmer L. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004, 22(19):2489-93. 10.1016/j.vaccine.2003.11.073, 15193413.
24. Rosati M, Valentin A, Jalah R, Patel V, von Gegerfelt A, Bergamaschi C, Alicea C, Weiss D, Treece J, Pal R, Markham PD, Marques ET, August JT, Khan A, Draghia-Akli R, Felber BK, Pavlakis GN. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 2008, 26(40):5223-9. 10.1016/j.vaccine.2008.03.090, 18468743.
25. Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, Martin JE, Rucker S, Andrews CA, Gomez PL, Mascola JR, Nabel GJ, Graham BS, . VRC 007 Study Team Phase I clinical evaluation ofa six-plasmid multiclade HIV-l DNA candidate vaccine. Vaccine 2007, 25(20):4085-92. Epub 2007 Mar 7, 10.1016/j.vaccine.2007.02.050, 17391815.
26. Harari A, Bart P, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl J, Esteban M, Heeney J, Frachette M, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. The Journal of Experimental Medicine 2008, 205(1):63-77. 10.1084/jem.20071331, 2234371, 18195071.
27. Jacobson MA, Adler SP, Sinclair E, Black D, Smith A, Chu A, Moss RB, Wloch MK. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine 2009, 27(10):1540-1548. 10.1016/j.vaccine.2009.01.006, 19168107.
28. O'Hagan D, Singh M, Ugozzoli M, Wild C, Barnett S, Chen M, Schaefer M, Doe B, Otten GR, Ulmer JB. Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines. Journal of Virology 2001, 75(19):9037-9043. 10.1128/JVI.75.19.9037-9043.2001, 114472, 11533167.
29. Wloch MK, Smith LR, Boutsaboualoy S, Reyes L, Han C, Kehler J, Smith HD, Selk L, Nakamura R, Brown JM, Marbury T, Wald A, Rolland A, Kaslow D, Evans T, Boeckh M. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adultsubjects. J Infect Dis 2008, 197(12):1634-42. 10.1086/588385, 18444883.
30. Lalor PA, Webby RJ, Morrow J, Rusalov D, Kaslow DC, Rolland A, Smith LR. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with ANietharnl1203/04 (H5Nl) influenza virus. J Infect Dis 2008, 197(12):1643-52. 10.1086/588431, 18513153.
31. Pan CH, Jimenez GS, Nair N, Wei Q, Adams RJ, Polack FP, Rolland A, Vilalta A, Griffin DE. Use of Vaxfectin Adjuvant with DNA Vaccine Encoding the Measles Virus Hemagglutinin and Fusion Proteins Protects Juvenile and Infant Rhesus Macaques against Measles Virus. Clin Vaccine Immunol 2008, 15(8):1214-21. Epub 2008 Jun 4, 10.1128/CVI.00120-08, 2519314, 18524884.
32. Smith L. Vaxfectin-formulated pandemic influenza DNA vaccines: preliminary clinical results. Paper presented at: IBC Life Sciences' Next Generation Vaccines; National Harbor, MD 2008,
33. Fort Dodge Animal Health Care Products. , http://www.wyeth.com/animalhealth
34. Novartis Animal Health. , http://www.ah.novartis.com/aqua/en/index.shtml
35. Memorial Sloan Kettering Cancer Center. , http://www.mskcc.org/mskcc/html/52438.cfm
36. World Health Organization. , http://www.who.int/csr/disease/influenza/en/
37. MMWR. 2009, 58(19):521-524., http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5819a1.htm
38. Forde GM. Rapid-response vaccines- Does DNA offer a solution. Nature Biotechnology 2005, 23(9):1059-1062. 10.1038/nbt0905-1059, 16151391.